Tagitanlimab clinical trials
How each study uses tagitanlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tagitanlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 7
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (3) · West China Hospital (2) · Peking Union Medical College Hospital (1) · Sun Yat-sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Henan Cancer Hospital (1) · Tianjin Medical University Second Hospital (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test tagitanlimab.
- Dec 2026A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)Phase 2 · Henan Cancer Hospital
- Dec 2026Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell CarcinomaPhase 2 · West China Hospital
- Jun 2027Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)Phase 2 · Tianjin Medical University Second Hospital
Studies
Open first, then newest update. How each study uses tagitanlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological MalignanciesNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07738757Written as TagitanlimabHow we know
- Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07701681Written as Sacituzumab Tirumotecan + TagitanlimabHow we know
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell CarcinomaRecruitingPhase 2West China HospitalNCT07492914Written as TagitanlimabHow we know
- Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)RecruitingPhase 2Tianjin Medical University Second HospitalNCT07179783Written as TagitanlimabHow we know
- Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07153965Written as Sacituzumab Tirumotecan plus TagitanlimabHow we know
- SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast CancerNot yet recruitingPhase 2West China HospitalNCT07109284Written as TagitanlimabHow we know
- A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)Not yet recruitingPhase 2Henan Cancer HospitalNCT07108816Written as Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimabHow we know
- KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingPhase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT05294172Written as KL-A167How we know
- KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT03848286Written as KL-A167 InjectionHow we know
- An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's LymphomaCompletedPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT03580564Written as KL-A167How we know
Given beside what is tested · 3 — tagitanlimab is usual care or a partner of the new treatment
- SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.RecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT05351788Written as KL-A167How we know
- SKB500 Combinations in Patients With Small Cell Lung CancerRecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07296809Written as KL-A167 InjectionHow we know
- SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerCompletedPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT05445908Written as KL-A167How we know
Codes
What other systems call tagitanlimab · ClinicalTrials.gg INT016709
- UNII (FDA) GUY458P83PTAGITANLIMABOne source FDA
- NCI Thesaurus C163992TagitanlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | GUY458P83P | TAGITANLIMAB | One source FDA |
| NCI Thesaurus | C163992 | Tagitanlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.